Joel Baglole

Joel Baglole

InvestorPlace Contributor

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

7 Best Bargain Stocks to Buy in October

By Joel Baglole, InvestorPlace Contributor

There are still deals to be found in the stock market. After a brutal September, these bargain stocks to buy can end the year with gains.

FB Stock Remains A Buy Despite Recent Drama

By Joel Baglole, InvestorPlace Contributor

How bad will things get for Facebook? That's the question investors and analysts are trying to answer coming off a very bad week for the social network. After a series of articles in The Wall Street Journal dubbed "The Facebook Files" detailed how the company encourages conflict and discord for it own profits, Facebook was raked over the coals in a televised interview with Frances Haugen, a former product manager within the company turned whistleblower.

3 Best Fitness Stocks to Buy for a Financially Fit Q4

By Joel Baglole, InvestorPlace Contributor

These fitness stocks are on different paths, but analyst sentiment indicates that each has upside based on their underlying fundamentals.

Buy Amazon Stock Before the Next Leg Up

By Joel Baglole, InvestorPlace Contributor

AMZN stock has been lagging this year, but it may be poised for a breakout on strong earnings results and robust consumer spending in Q4.

Novavax Stock Will Find Its Bottom, But Probably not Soon

By Joel Baglole, InvestorPlace Contributor

Down nearly 40% over the past month, NVAX stock has been on a steep decline that appears to be accelerating. At its current price of $163.06 per share, Novavax's stock is now 50% below its all-time high of $331.68 reached in February of this year. With the current slide showing no signs of stopping, shareholders may want to cut their losses.

Load More